Literature DB >> 27269966

Genetic risk of Parkinson's disease in the general population.

Sirwan K L Darweesh1, Vincentius J A Verlinden2, Hieab H H Adams2, André G Uitterlinden3, Albert Hofman1, Bruno H Stricker4, Cornelia M van Duijn1, Peter J Koudstaal5, M Arfan Ikram6.   

Abstract

INTRODUCTION: We investigated whether a risk score based on genetic risk variants for Parkinson's disease (PD) is associated with the risk and improves prediction of incident PD, and whether the risk score is associated with basic activities of daily living (BADL) in healthy individuals.
METHODS: Within the population-based Rotterdam Study, we genotyped 26 independent risk variants for PD and constructed a genetic risk score in 7167 participants who were free of parkinsonism and dementia at baseline (1990 or 2000). Participants were followed for a maximum of twenty years for the onset of parkinsonism, dementia or death until January 1, 2011 (median follow-up 12.1 years). We studied the relationship between the genetic risk score and incident PD with adjustment for age, sex, smoking and parental history. In an independent sample of 2997 persons free of parkinsonism and dementia, we studied whether the PD risk score was associated with impaired BADL.
RESULTS: During follow-up (median 12.1 years), 99 persons were diagnosed with incident PD. The genetic risk score was associated with incident PD (hazard ratio per standard deviation risk 1.25 [95% confidence interval = 1.02; 1.55]), but did not substantially improve prediction (change in C-statistic 0.687 [0.628; 0.745] to 0.698 [0.635; 0.760], ΔC = 0.011 [-0.011; 0.033]). The genetic risk score was associated with a higher probability of any impairment in BADL (odds ratio = 1.11 [1.00; 1.23]).
CONCLUSION: Genetic variants for PD are associated with the risk of incident PD in the general population and with impairment in daily functioning in individuals without clinical parkinsonism, but do not improve the clinical prediction of PD. However, we were probably underpowered to detect a small improvement in PD prediction.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Genetic association study; Parkinson’s disease

Mesh:

Year:  2016        PMID: 27269966     DOI: 10.1016/j.parkreldis.2016.05.030

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  5 in total

1.  The Rotterdam Study: 2018 update on objectives, design and main results.

Authors:  M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman
Journal:  Eur J Epidemiol       Date:  2017-10-24       Impact factor: 8.082

2.  Polygenic Risk Scores in a Prospective Parkinson's Disease Cohort.

Authors:  Ming-Wei Sia; Jia-Nee Foo; Seyed-Ehsan Saffari; Aidan Sheng-Yong Wong; Chiea-Chuen Khor; Jian-Min Yuan; Eng-King Tan; Woon-Puay Koh; Louis Chew-Seng Tan
Journal:  Mov Disord       Date:  2021-08-17       Impact factor: 10.338

3.  Combined accelerometer and genetic analysis to differentiate essential tremor from Parkinson's disease.

Authors:  Bhuvan Molparia; Brian N Schrader; Eli Cohen; Jennifer L Wagner; Sandeep R Gupta; Sherrie Gould; Nelson Hwynn; Emily G Spencer; Ali Torkamani
Journal:  PeerJ       Date:  2018-07-20       Impact factor: 2.984

4.  Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank.

Authors:  Benjamin Meir Jacobs; Daniel Belete; Jonathan Bestwick; Cornelis Blauwendraat; Sara Bandres-Ciga; Karl Heilbron; Ruth Dobson; Mike A Nalls; Andrew Singleton; John Hardy; Gavin Giovannoni; Andrew John Lees; Anette-Eleonore Schrag; Alastair J Noyce
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-10       Impact factor: 10.154

Review 5.  Towards early disease modification of Parkinson's disease: a review of lessons learned in the Alzheimer field.

Authors:  Marthe Smedinga; Sirwan K L Darweesh; Bastiaan R Bloem; Bart Post; Edo Richard
Journal:  J Neurol       Date:  2020-08-18       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.